GEN: Baxter Gains Rights to Recombinant Protein for Treatment of Thrombotic Thrombocytopenic Purpura Baxter Gains Rights to Recombinant Protein for Treatment of Thrombotic Thrombocytopenic Purpura Business Wire: U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Sanofi announced that the Food and Drug Administration (FDA) has approved Cablivi (caplacizumab-yhdp) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in ...
Please provide your email address to receive an email when new articles are posted on . Patients with acquired thrombotic thrombocytopenic purpura experienced a faster normalization of platelet count ... Healio: Low-dose rituximab induces high response rates in acquired thrombotic thrombocytopenic purpura News Medical: Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura In a new study by Yale Cancer Center (YCC) researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care ... Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively.
